IceCure Medical Ltd.
Business
IceCure Medical Ltd. is a commercial-stage medical device company developing minimally invasive cryoablation systems using liquid nitrogen to ablate benign and malignant tumors. The company manufactures the ProSense system and disposable CryoProbes for treating breast, lung, kidney, and bone tumors, as well as endometriosis and nerve ablation. IceCure markets its products through direct sales in the United States and distributor agreements across Europe, Asia, and other regions, with regulatory approvals in multiple jurisdictions including FDA clearance for ProSense in breast cancer treatment.
Summary from 20-F filed 2026-03-17
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $3.38M |
| Net income | $-15.06M |
| Total assets | $13.89M |
| Total liabilities | — |
| Stockholders' equity | $9.05M |
| Operating cash flow | $-14.57M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is IceCure Medical Ltd.'s CIK number?
IceCure Medical Ltd.'s SEC CIK number is 0001584371 (1584371). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find IceCure Medical Ltd.'s SEC filings?
All of IceCure Medical Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.